Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma

In the early stages of epithelial ovarian cancer, histopathological grading is important. However, the grading of ovarian clear cell carcinoma (OCCC) remains controversial. We aimed to identify irregular giant nuclear cells (IGNCs) by a simple method in clinical practice, and to evaluate the prognos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pathology oncology research 2011-09, Vol.17 (3), p.605-611
Hauptverfasser: Matsumoto, Naoki, Umezawa, Takashi, Sasaki, Toru, Nakajima, Kuninobu, Kanetsuna, Yukiko, Sasaki, Hiroshi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 611
container_issue 3
container_start_page 605
container_title Pathology oncology research
container_volume 17
creator Matsumoto, Naoki
Umezawa, Takashi
Sasaki, Toru
Nakajima, Kuninobu
Kanetsuna, Yukiko
Sasaki, Hiroshi
description In the early stages of epithelial ovarian cancer, histopathological grading is important. However, the grading of ovarian clear cell carcinoma (OCCC) remains controversial. We aimed to identify irregular giant nuclear cells (IGNCs) by a simple method in clinical practice, and to evaluate the prognostic value of IGNCs in pT1 OCCC. Eighty-seven pT1 OCCC patients who underwent initial surgery at Jikei University Kashiwa Hospital, Chiba, Japan, were retrospectively assessed. Paraffin-embedded tissue sections (PTSs) stained with hematoxylin and eosin were reviewed. Giant nuclear cells (GNCs) were defined as cells with a nuclear length of more than twice the median nuclear length. GNCs with irregular nuclear circumferences were defined as IGNCs. Cases where one or more GNCs existed and where IGNCs accounted for >10% of the GNCs were classified as IGNC-positive. We also attempted to identify IGNCs on touch imprint cytology smears (TICSs). Among the 87 cases, 68 were IGNC-negative and 19 were IGNC-positive. The 5-year disease-free and overall survival rates were 88.9% and 90.3% in the total patients, 98.3% and 100% in the IGNC-negative group, and 59.7% and 62.0% in the IGNC-positive group, respectively. These survival rates were significantly lower in the IGNC-positive group than in the IGNC-negative group (adjusted hazard ratio = 14, 95% confidence interval = 2.7–124 and adjusted hazard ratio = 25, 95% confidence interval = 2.9–768, respectively). Prognostic differences were not identified for other factors. IGNC identification on 28 available TICSs predicted IGNC identification on PTSs (sensitivity = 50.0%, specificity = 100%, P  = 0.007). The presence of IGNCs has clinical and prognostic value for pT1 OCCC.
doi_str_mv 10.1007/s12253-010-9356-5
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_884848230</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2788361671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c323t-b03a54fb698ec24ea263c9a55f9da6ca83ea0f2788a9ab4a2039fadb0917e2eb3</originalsourceid><addsrcrecordid>eNp1kUtLxDAUhYMovn-AGwm4cFXNo0mbpRQdBVEXo9twm7kdK510TFrBf290RhHBZJHc3O-cXDiEHHF2xhkrziMXQsmMcZYZqXSmNsguV1JkomTFZroLbrLcKL1D9mJ8YUmjjd4mO4KLIteF3CWh6lrfOugo-Bl9CP3c93FoHX2CbkTaN3R4xvSOEb37qm9CwPnYQaCTFvxA70bXYaoq7LpIW0-XU07v3yCkLq1-WrSC4FrfL-CAbDXQRTxcn_vk8epyWl1nt_eTm-riNnNSyCGrmQSVN7U2JTqRIwgtnQGlGjMD7aCUCKwRRVmCgToHwaRpYFYzwwsUWMt9crryXYb-dcQ42EUbXRoFPPZjtGWZpy0kS-TJH_KlH4NPw1meVqkU03mi-IpyoY8xYGOXoV1AeLec2c887CoPm_Kwn3lYlTTHa-exXuDsR_EdQALECoip5ecYfn39r-sH8Y6VDQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1111855064</pqid></control><display><type>article</type><title>Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Matsumoto, Naoki ; Umezawa, Takashi ; Sasaki, Toru ; Nakajima, Kuninobu ; Kanetsuna, Yukiko ; Sasaki, Hiroshi</creator><creatorcontrib>Matsumoto, Naoki ; Umezawa, Takashi ; Sasaki, Toru ; Nakajima, Kuninobu ; Kanetsuna, Yukiko ; Sasaki, Hiroshi</creatorcontrib><description>In the early stages of epithelial ovarian cancer, histopathological grading is important. However, the grading of ovarian clear cell carcinoma (OCCC) remains controversial. We aimed to identify irregular giant nuclear cells (IGNCs) by a simple method in clinical practice, and to evaluate the prognostic value of IGNCs in pT1 OCCC. Eighty-seven pT1 OCCC patients who underwent initial surgery at Jikei University Kashiwa Hospital, Chiba, Japan, were retrospectively assessed. Paraffin-embedded tissue sections (PTSs) stained with hematoxylin and eosin were reviewed. Giant nuclear cells (GNCs) were defined as cells with a nuclear length of more than twice the median nuclear length. GNCs with irregular nuclear circumferences were defined as IGNCs. Cases where one or more GNCs existed and where IGNCs accounted for &gt;10% of the GNCs were classified as IGNC-positive. We also attempted to identify IGNCs on touch imprint cytology smears (TICSs). Among the 87 cases, 68 were IGNC-negative and 19 were IGNC-positive. The 5-year disease-free and overall survival rates were 88.9% and 90.3% in the total patients, 98.3% and 100% in the IGNC-negative group, and 59.7% and 62.0% in the IGNC-positive group, respectively. These survival rates were significantly lower in the IGNC-positive group than in the IGNC-negative group (adjusted hazard ratio = 14, 95% confidence interval = 2.7–124 and adjusted hazard ratio = 25, 95% confidence interval = 2.9–768, respectively). Prognostic differences were not identified for other factors. IGNC identification on 28 available TICSs predicted IGNC identification on PTSs (sensitivity = 50.0%, specificity = 100%, P  = 0.007). The presence of IGNCs has clinical and prognostic value for pT1 OCCC.</description><identifier>ISSN: 1219-4956</identifier><identifier>EISSN: 1532-2807</identifier><identifier>DOI: 10.1007/s12253-010-9356-5</identifier><identifier>PMID: 21274673</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Adenocarcinoma, Clear Cell - pathology ; Adenocarcinoma, Clear Cell - surgery ; Adult ; Aged ; Aged, 80 and over ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Cell Nucleus - pathology ; Female ; Humans ; Immunology ; Middle Aged ; Neoplasm Staging ; Oncology ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - surgery ; Pathology ; Prognosis ; Retrospective Studies ; Survival Rate</subject><ispartof>Pathology oncology research, 2011-09, Vol.17 (3), p.605-611</ispartof><rights>Arányi Lajos Foundation 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c323t-b03a54fb698ec24ea263c9a55f9da6ca83ea0f2788a9ab4a2039fadb0917e2eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12253-010-9356-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12253-010-9356-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21274673$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsumoto, Naoki</creatorcontrib><creatorcontrib>Umezawa, Takashi</creatorcontrib><creatorcontrib>Sasaki, Toru</creatorcontrib><creatorcontrib>Nakajima, Kuninobu</creatorcontrib><creatorcontrib>Kanetsuna, Yukiko</creatorcontrib><creatorcontrib>Sasaki, Hiroshi</creatorcontrib><title>Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma</title><title>Pathology oncology research</title><addtitle>Pathol. Oncol. Res</addtitle><addtitle>Pathol Oncol Res</addtitle><description>In the early stages of epithelial ovarian cancer, histopathological grading is important. However, the grading of ovarian clear cell carcinoma (OCCC) remains controversial. We aimed to identify irregular giant nuclear cells (IGNCs) by a simple method in clinical practice, and to evaluate the prognostic value of IGNCs in pT1 OCCC. Eighty-seven pT1 OCCC patients who underwent initial surgery at Jikei University Kashiwa Hospital, Chiba, Japan, were retrospectively assessed. Paraffin-embedded tissue sections (PTSs) stained with hematoxylin and eosin were reviewed. Giant nuclear cells (GNCs) were defined as cells with a nuclear length of more than twice the median nuclear length. GNCs with irregular nuclear circumferences were defined as IGNCs. Cases where one or more GNCs existed and where IGNCs accounted for &gt;10% of the GNCs were classified as IGNC-positive. We also attempted to identify IGNCs on touch imprint cytology smears (TICSs). Among the 87 cases, 68 were IGNC-negative and 19 were IGNC-positive. The 5-year disease-free and overall survival rates were 88.9% and 90.3% in the total patients, 98.3% and 100% in the IGNC-negative group, and 59.7% and 62.0% in the IGNC-positive group, respectively. These survival rates were significantly lower in the IGNC-positive group than in the IGNC-negative group (adjusted hazard ratio = 14, 95% confidence interval = 2.7–124 and adjusted hazard ratio = 25, 95% confidence interval = 2.9–768, respectively). Prognostic differences were not identified for other factors. IGNC identification on 28 available TICSs predicted IGNC identification on PTSs (sensitivity = 50.0%, specificity = 100%, P  = 0.007). The presence of IGNCs has clinical and prognostic value for pT1 OCCC.</description><subject>Adenocarcinoma, Clear Cell - pathology</subject><subject>Adenocarcinoma, Clear Cell - surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Cell Nucleus - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunology</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - surgery</subject><subject>Pathology</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><issn>1219-4956</issn><issn>1532-2807</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kUtLxDAUhYMovn-AGwm4cFXNo0mbpRQdBVEXo9twm7kdK510TFrBf290RhHBZJHc3O-cXDiEHHF2xhkrziMXQsmMcZYZqXSmNsguV1JkomTFZroLbrLcKL1D9mJ8YUmjjd4mO4KLIteF3CWh6lrfOugo-Bl9CP3c93FoHX2CbkTaN3R4xvSOEb37qm9CwPnYQaCTFvxA70bXYaoq7LpIW0-XU07v3yCkLq1-WrSC4FrfL-CAbDXQRTxcn_vk8epyWl1nt_eTm-riNnNSyCGrmQSVN7U2JTqRIwgtnQGlGjMD7aCUCKwRRVmCgToHwaRpYFYzwwsUWMt9crryXYb-dcQ42EUbXRoFPPZjtGWZpy0kS-TJH_KlH4NPw1meVqkU03mi-IpyoY8xYGOXoV1AeLec2c887CoPm_Kwn3lYlTTHa-exXuDsR_EdQALECoip5ecYfn39r-sH8Y6VDQ</recordid><startdate>20110901</startdate><enddate>20110901</enddate><creator>Matsumoto, Naoki</creator><creator>Umezawa, Takashi</creator><creator>Sasaki, Toru</creator><creator>Nakajima, Kuninobu</creator><creator>Kanetsuna, Yukiko</creator><creator>Sasaki, Hiroshi</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20110901</creationdate><title>Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma</title><author>Matsumoto, Naoki ; Umezawa, Takashi ; Sasaki, Toru ; Nakajima, Kuninobu ; Kanetsuna, Yukiko ; Sasaki, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c323t-b03a54fb698ec24ea263c9a55f9da6ca83ea0f2788a9ab4a2039fadb0917e2eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adenocarcinoma, Clear Cell - pathology</topic><topic>Adenocarcinoma, Clear Cell - surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Cell Nucleus - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunology</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - surgery</topic><topic>Pathology</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsumoto, Naoki</creatorcontrib><creatorcontrib>Umezawa, Takashi</creatorcontrib><creatorcontrib>Sasaki, Toru</creatorcontrib><creatorcontrib>Nakajima, Kuninobu</creatorcontrib><creatorcontrib>Kanetsuna, Yukiko</creatorcontrib><creatorcontrib>Sasaki, Hiroshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Pathology oncology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsumoto, Naoki</au><au>Umezawa, Takashi</au><au>Sasaki, Toru</au><au>Nakajima, Kuninobu</au><au>Kanetsuna, Yukiko</au><au>Sasaki, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma</atitle><jtitle>Pathology oncology research</jtitle><stitle>Pathol. Oncol. Res</stitle><addtitle>Pathol Oncol Res</addtitle><date>2011-09-01</date><risdate>2011</risdate><volume>17</volume><issue>3</issue><spage>605</spage><epage>611</epage><pages>605-611</pages><issn>1219-4956</issn><eissn>1532-2807</eissn><abstract>In the early stages of epithelial ovarian cancer, histopathological grading is important. However, the grading of ovarian clear cell carcinoma (OCCC) remains controversial. We aimed to identify irregular giant nuclear cells (IGNCs) by a simple method in clinical practice, and to evaluate the prognostic value of IGNCs in pT1 OCCC. Eighty-seven pT1 OCCC patients who underwent initial surgery at Jikei University Kashiwa Hospital, Chiba, Japan, were retrospectively assessed. Paraffin-embedded tissue sections (PTSs) stained with hematoxylin and eosin were reviewed. Giant nuclear cells (GNCs) were defined as cells with a nuclear length of more than twice the median nuclear length. GNCs with irregular nuclear circumferences were defined as IGNCs. Cases where one or more GNCs existed and where IGNCs accounted for &gt;10% of the GNCs were classified as IGNC-positive. We also attempted to identify IGNCs on touch imprint cytology smears (TICSs). Among the 87 cases, 68 were IGNC-negative and 19 were IGNC-positive. The 5-year disease-free and overall survival rates were 88.9% and 90.3% in the total patients, 98.3% and 100% in the IGNC-negative group, and 59.7% and 62.0% in the IGNC-positive group, respectively. These survival rates were significantly lower in the IGNC-positive group than in the IGNC-negative group (adjusted hazard ratio = 14, 95% confidence interval = 2.7–124 and adjusted hazard ratio = 25, 95% confidence interval = 2.9–768, respectively). Prognostic differences were not identified for other factors. IGNC identification on 28 available TICSs predicted IGNC identification on PTSs (sensitivity = 50.0%, specificity = 100%, P  = 0.007). The presence of IGNCs has clinical and prognostic value for pT1 OCCC.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>21274673</pmid><doi>10.1007/s12253-010-9356-5</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1219-4956
ispartof Pathology oncology research, 2011-09, Vol.17 (3), p.605-611
issn 1219-4956
1532-2807
language eng
recordid cdi_proquest_miscellaneous_884848230
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Adenocarcinoma, Clear Cell - pathology
Adenocarcinoma, Clear Cell - surgery
Adult
Aged
Aged, 80 and over
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cell Nucleus - pathology
Female
Humans
Immunology
Middle Aged
Neoplasm Staging
Oncology
Ovarian Neoplasms - pathology
Ovarian Neoplasms - surgery
Pathology
Prognosis
Retrospective Studies
Survival Rate
title Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T12%3A36%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20and%20Prognostic%20Value%20of%20the%20Presence%20of%20Irregular%20Giant%20Nuclear%20Cells%20in%20pT1%20Ovarian%20Clear%20Cell%20Carcinoma&rft.jtitle=Pathology%20oncology%20research&rft.au=Matsumoto,%20Naoki&rft.date=2011-09-01&rft.volume=17&rft.issue=3&rft.spage=605&rft.epage=611&rft.pages=605-611&rft.issn=1219-4956&rft.eissn=1532-2807&rft_id=info:doi/10.1007/s12253-010-9356-5&rft_dat=%3Cproquest_cross%3E2788361671%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1111855064&rft_id=info:pmid/21274673&rfr_iscdi=true